Spermosens AB (“Spermosens” or “the Company”) announces that the last day of trading for the warrants of series TO 4 on Spotlight Stock Market is 27 November 2025.
Spermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (ZL 2019800555646) has been granted in China. The patent covers the Company’s method for measuring sperm binding to the egg receptor JUNO, a critical biological interaction during fertilization that no existing standard test can evaluate.
After demonstrating the diagnostic value of JUNO-Checked earlier this year, we have now taken the next steps preparing for the market.
Spermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (IL 280445) has been granted in Israel. The patent covers the company’s unique method for measuring sperm binding to the egg receptor JUNO, a critical biological interaction during fertilization that no existing test can evaluate.
Spermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (MX/a/2021/002145) has been granted in Mexico. The patent covers the company’s unique method for measuring sperm binding to the egg, a critical biological interaction during fertilization that no existing test can evaluate.
Spermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (CA 3,109,529) has been granted in Canada. The patent covers the company’s unique method for measuring sperm binding to the egg receptor JUNO — a critical biological interaction during fertilization that no existing test can evaluate.
We achieved a pivotal milestone during the second quarter, as strong clinical results clearly confirmed the diagnostic value of JUNO-Checked.
Spermosens AB (“Spermosens” or the “Company”) today provides a status update following the successful completion of its clinical study with the second-generation JUNO-Checked system and the full subscription of TO5 warrants. These milestones strengthen the Company’s position as it advances its diagnostic technology towards commercialization.
Spermosens AB (publ) (“Spermosens” or the “Company”) today announces the outcome of the exercise of warrants of series TO 5 (the “Warrants”). A total of 467,740,274 shares were subscribed for through the exercise of Warrants, corresponding to an exercise rate of 100 percent. Spermosens will receive proceeds of approximately SEK 2.6 million before transaction costs.
Spermosens AB ("Spermosens" or the "Company") today held its Annual General Meeting in Lund. The following resolutions were adopted: The Annual Report and Auditor’s Report for the financial year 2024 were presented. CEO Tore Duvold provided a summary of the Company’s…
Spermosens AB (“Spermosens” or the “Company”) today announces that the Chairman of the Board, Ulrik Spork, and the CEO, Tore Duvold, have exercised their respective warrants of series TO5 for the subscription of new shares in the Company. Ulrik Spork has exercised 6,446,200…
Spermosens AB (“Spermosens” or the “Company”) today announces positive topline results from its clinical study conducted at the Reproductive Medicine Center (RMC) in Malmö. The study was designed to validate the diagnostic value of the Company’s patented JUNO-Checked system and has now reached a successful conclusion.
The results demonstrate a statistically significant correlation between the JUNO Score, a measurement of sperm binding to the JUNO receptor, and fertilization rate in IVF.
